Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OXGN)

UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

GlobeNewswire June 20, 2016

OXiGENE Announces Name Change to Mateon Therapeutics

GlobeNewswire June 17, 2016

OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

GlobeNewswire June 10, 2016

OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

GlobeNewswire May 24, 2016

Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors

GlobeNewswire May 20, 2016

OXiGENE Reports First Quarter 2016 Financial Results

GlobeNewswire May 9, 2016

Oxigene Receives Fast Track Designation From U.S. FDA for CA4P

GlobeNewswire March 30, 2016

OXiGENE Reports 2015 Financial Results

GlobeNewswire March 28, 2016

OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

GlobeNewswire March 25, 2016
View More News ››

Opinion & Analysis (NDAQ:OXGN)

Stockhouse blogger focuses on out-of-favour biotech stocks (ROSG) (OXGN)

Stockhouse Editorial April 15, 2014
View More Opinion ››

Bullboard Posts (NDAQ:OXGN)

RE: OXGN to $2.5 vERY SOON

Hope you're right! I bought 1500 share today, so maybe in time for a strong return...
alek - November 25, 2011

OXGN to $2.5 vERY SOON

Gerrygoldbug - October 31, 2011

The most undervalued BIO out there

Gerrygoldbug - October 26, 2011

RE: RE: Buy time!

I bought 10 K @ 0.321.  I think we might see this stock pop up to 0.50 by weeks end.  The shorts are going to keep this one...
OILBOY1 - September 13, 2010

RE: Buy time!

It does look like a turning point
InarRocks - September 13, 2010

Buy time!

This stock reads buy! Make money now, buy this stock!!
tradinmaniac - September 13, 2010
View more Bullboard ››

Anfield Energy Inc

Anfield Energy Inc

Anfield Energy Inc. is a Canada-based uranium and vanadium development and near-term production company. A key asset in the ...
View More »